Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates
E-Mail IMAGE: A preclinical study shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology, using... view more Credit: MD Anderson Cancer Center Abstract #LB008 HOUSTON -- A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology,...